Key result
Epstein-Barr virus glycine-alanine repeats inhibit premature mRNA translation into antigenic precursors to evade immune surveillance.
Why the study?
The molecular characteristics of defective ribosomal products (DRiPs) involved in rapid pMHC I presentation during immune surveillance were not known.
The study provides the first characterization of virus DRiPs as truncated translation products, revealing how EBV may evade immune surveillance by down-regulating DRiP production.
May open EBV immunotherapy avenues; leaves open human disease relevance.
BACKGROUND: Cytotoxic T cells detect intracellular pathogens by surveying peptide loaded MHC class I molecules (pMHC I) on the cell surface. Effective immune surveillance also requires infected cells to present pMHC I promptly before viral progeny can escape. Rapid pMHC I presentation apparently occurs because infected cells can synthesize and present peptides from antigenic precursors called defective ribosomal products (DRiPs). The molecular characteristics of DRiPs are not known. METHODOLOGY/PRINCIPAL FINDINGS: Here, using a novel method for detecting antigenic precursors and proteolytic intermediates, we tracked the synthesis and processing of Epstein-Barr Virus encoded nuclear antigen 1 (EBNA1). We find that ribosomes initiated translation appropriately, but rapidly produced DRiPs representing approximately 120 amino acid truncated EBNA1 polypeptides by premature termination. Moreover, specific sequences in EBNA1 mRNA strongly inhibited the generation of truncated DRiPs and pMHC I presentation. SIGNIFICANCE: Our results reveal the first characterization of virus DRiPs as truncated translation products. Furthermore, production of EBNA1-derived DRiPs is down-regulated in cells, possibly limiting the antigenicity of EBNA1.
No takes yet. Share an insight, caveat, or question.
Cardinaud et al. (2010) studied Epstein-Barr Virus (EBV) immune evasion. EBNA1 mRNA translation vs. EBNA1 lacking glycine-alanine repeat (GAr) was evaluated. Translation of Epstein-Barr Virus EBNA1 mRNA is prematurely terminated to produce truncated antigenic precursors (DRiPs), a process inhibited by the glycine-alanine repeat sequence to evade immune surveillance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: